ANS03 for Advanced Solid Tumors with ROS1 or NTRK Alteration
A Study to Investigate ANS03 in Participants With Locally Advanced or Metastatic Solid Tumors
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 1
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 96 (estimated)
- Sponsor
- Avistone Biotechnology Co., Ltd. · Industry
This trial is looking for adults with advanced solid tumors that have specific genetic changes (ROS1 or NTRK). Participants will take a medication called ANS03 to see how safe it is and how well it works.
You may be able to join if
- I am at least 18 years old
- I have a life expectancy of at least 12 weeks
- I have measurable disease according to certain guidelines
- I have a documented ROS1 or NTRK alteration
- I have a performance status of 0-2
You may not be able to join if
- I have an active infection like tuberculosis or HIV
- I have untreated brain metastases
- I have serious heart or brain blood vessel diseases
- I have cancer in the meninges or spinal cord compression
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your EligibilityThis is a first-in-human Phase I, multi-center, open-label study of ANS03 in patients with advanced solid tumors. The study evaluates the safety, tolerability, preliminary efficay, pharmacokinetics, anti-tumor activity of ANS03 as monotherapy.
Loading trial locations…